Enzene Biosciences, a wholly owned subsidiary of Alkem Laboratories Ltd, experienced a cyberattack targeting its U.S. operations, where threat actors compromised business email accounts of certain employees. The attackers exploited these compromised emails to execute a fraudulent transfer of funds, though the exact financial loss remains under investigation. The incident was disclosed in a regulatory filing on May 15, 2025, with Alkem Laboratories engaging independent cybersecurity firms for a forensic analysis.No theft of intellectual property or clinical data was reported, but the attack highlights risks associated with Business Email Compromise (BEC), a common tactic where trusted communication channels are manipulated to initiate unauthorized transactions. The company emphasized transparency and governance by publicly reporting the breach to stock exchanges (BSE and NSE) and cooperating with regulators. While the full financial and reputational impact is still being assessed, the incident underscores the pharmaceutical industry’s vulnerability to cyber threats, particularly those targeting subsidiaries with weaker security controls.